Complaint Alleges Ellume Failed To Pay Refunds After Class I Recall Of OTC COVID-19 Tests
Executive Summary
Complaint filed in Maryland federal court says Australian firm, which received more than $230 from US government to boost production of its OTC COVID-19 diagnostic tests available to US consumers, should’ve offered refunds to consumers who bought tests the company has recalled due to false positive tests.
You may also be interested in...
Recall Of Millions Of Ellume COVID-19 Tests High-Risk Class I, FDA Says
Ellume recalled 2,212,335 of the home tests because there’s a chance they can give false-positive results.
US Supply Of OTC COVID-19 Tests Gets Boost Through $231.8M Contract For Australian Firm
Biden administration seems to be betting Elluve's OTC at-home antigen diagnostic test will be a game changer in helping stop the spread of the coronavirus.
Joint Mission: FDA And VA Partner On Device Development Initiative
The US Food and Drug Administration and the Veterans Health Administration are partnering to create tools that can help novel technology reach patients more quickly and easily.